12/31/2015 | IG | Market Commentary: Outlook 2016: Another record year for high-grade issuance; supply to be front-loaded in 2016
|
5/5/2015 | EMHYMUPFPV | Market Commentary: AbbieVie brings $16.7 billion deal; AT&T, Microsoft improve; Exxon, Canadian Pacific Rail soft
|
5/5/2015 | IG | Market Commentary: AbbieVie brings $16.7 billion deal; AT&T, Microsoft improve; Exxon, Canadian Pacific Rail soft
|
5/5/2015 | IG | New Issue: AbbVie prices $16.7 billion of notes in six parts for Pharmacyclics acquisition
|
3/5/2015 | BKIG | AbbVie to use committed financing for Pharmacyclics acquisition, plans to repurchase shares post-closing
|
2/9/2015 | SP | New Issue: JPMorgan prices $1 million 9% reverse exchangeables on Pharmacyclics
|
8/29/2014 | SP | New Issue: JPMorgan prices $710,000 14.8% reverse exchangeables linked to Pharmacyclics
|
7/15/2011 | CVHYPF | Pharmacyclics files $150 million shelf for preferreds, debt and stock
|
6/17/2011 | PP | Pharmacyclics inks $57.07 million registered direct offering of shares
|
6/17/2010 | PP | New Issue: Pharmacyclics lifts registered direct offering of stock to $52 million
|
6/17/2010 | PP | Market Commentary: Pharmacyclics ups direct offering; Celsion gets equity facility; China Power seals $10 million
|
6/16/2010 | PP | Market Commentary: Pharmacyclics brings offering; Kayne Anderson settles two deals; BNC adds Aquiline as investor
|
6/16/2010 | PP | New Issue: Pharmacyclics arranges $40 million registered direct offering of stock
|
5/20/2010 | CVHYPF | Pharmacyclics files $100 million shelf for preferreds, debt and stock
|
2/23/2009 | PP | New Issue: Pharmacyclics settles $1.4 million private placement of stock
|
2/23/2009 | PP | Market Commentary: Apollo completes $70 million deal; Queenston to raise C$18 million; Po Valley to issue stock
|
9/17/2008 | SS | Pharmacyclics shareholder Robert Duggan steps in after CEO, board members resign
|
2/21/2007 | SS | Market Commentary: Jupitermedia, Getty gain; Loral in focus on SatMex sale; Whole Foods, Wild Oats rise; Novastar falls
|
2/5/2007 | CVHY | Pharmacyclics files $100 million shelf registration
|
11/7/2006 | BT | New Issue: Pharmacyclics prices $19.95 million follow-on stock sale at $4.75 per share
|
10/30/2006 | BT | Pharmacyclics plans follow-on offering of 3.8 million shares via RBC, Thomas Weisel
|
10/26/2006 | BT | Pharmacyclics reports Q1 cash at $34.7 million, on track for Xcytrin filing
|
8/24/2006 | BT | Pharmacyclics reports net loss of $42.2 million for fiscal year, moves ahead with Xcytrin development
|
8/21/2006 | PP | Market Commentary: Inverness secures $151.25 million from stock offering; Oscient, unit completes private placements
|
8/21/2006 | BTPP | New Issue: Pharmacyclics receives $20 million equity line
|
8/11/2006 | BT | Pharmacyclics ends stockholder rights plan
|
8/11/2006 | BT | Market Commentary: Encysive spikes, slips to red; SkyePharma still looking for buyer; Pharmacyclics sinks
|
6/7/2006 | BT | RBC keeps Pharmacyclics at sector perform
|
6/5/2006 | BT | Pharmacyclics presents new data to support Xcytrin for brain cancer
|
6/5/2006 | BT | Market Commentary: Genelabs stock skyrockets on Novartis collaboration; Antigenics stock falls on phase 3 Oncophage data
|
5/9/2006 | BT | Pharmacyclics to submit NDA for Xcytrin to treat lung cancer with brain metastases
|
4/10/2006 | BT | Celera sells therapeutic programs to Pharmacyclics
|
12/19/2005 | BT | Pharmacyclics says Xcytrin not effective against brain metastases in non-small cell lung cancer study
|
12/12/2005 | BT | Pharmacyclics: Xcytrin/Zevalin combo shows anti-tumor activity in lymphoma patients
|
12/8/2005 | BT | Pharmacyclics' MGd improves survival rate in animal study of Lou Gehrig's
|
11/8/2005 | BT | Rodman & Renshaw initiates Pharmacyclics coverage at market outperform
|